The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | Daratumumab with ATRA in R/R MM
Patients with multiple myeloma (MM) that develop bortezomib and lenalidomide-resistant disease have a median survival of 9 months; this clearly illustrates that new anti-MM approaches are needed. Niels van de Donk, MD, PhD, VU University Medical Center, Amsterdam, The Netherlands, discusses the results of the phase I/II DARA/ATRA study (NCT02751255). This clinical trial assessed the efficacy and safety of daratumumab combined with all-trans retinoic acid (ATRA) in relapsed/refractory MM. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
